flumazenil

Flumazenil, which was first marketed in 1987, is a drug that has been used as an antidote in the treatment of benzodiazepine overdoses. There are, however, many complications that must be taken into consideration when used in the acute care setting. These include lowered seizure threshold, agitation, and anxiousness. Besides, Flumazenil's short half-life requires multiple doses. Because of the potential risks of withdrawal symptoms and the drug's short half-life, patients must be carefully monitored to prevent recurrence of overdose symptoms or adverse side effects. Bear in mind that this drug may also be effective in reducing excessive daytime sleepiness while improving vigilance in primary hypersomnias. It is worth noting that deaths have occurred in patients who received Flumazenil in a variety of clinical settings. In fact, the majority of deaths occurred in patients with serious underlying disease or in patients who had ingested large amounts of non-benzodiazepine drugs as part of an overdose.